Study guide
10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage
Key Takeaways Explain This Topic AI
A Glasgow-Blatchford score of 0-1 identifies patients who can be managed as outpatients without inpatient endoscopy.
Suspected variceal bleeding is treated with terlipressin and prophylactic antibiotics before endoscopy, which should occur within 24 hours, followed by band ligation.
Proton pump inhibitors are given after endoscopic haemostasis of a bleeding peptic ulcer, not routinely before endoscopy.
Last updated: September 2026
Acute gastrointestinal haemorrhage and colonic neoplasia are quintessential emergencies in acute internal medicine. Candidates must master resuscitation parameters, endoscopic risk stratification, targeted endoscopic and pharmacological haemostasis for non-variceal and variceal bleeding, diverticular disease staging, and the genetic architecture of hereditary colorectal cancer syndromes.
1. Acute Upper Gastrointestinal Bleeding (UGIB) & Risk Stratification
Acute upper GI bleeding (bleeding originating proximal to the suspensory ligament of Treitz at the duodenojejunal flexure) carries an overall in-hospital mortality of 8–10%. Common aetiologies comprise peptic ulcer disease (~50%), oesophageal and gastric varices (~10–15%), Mallory-Weiss tears (~5–10%), erosive gastroduodenitis (~10%), and upper GI malignancies (~3–5%).
Resuscitation & Restrictive Transfusion Policy
Airway, Breathing, Circulation (A-B-C): High-flow oxygen if hypoxic; protect the airway in patients with massive haematemesis or altered mental status (early elective endotracheal intubation prevents fatal aspiration). Insert two large-bore peripheral IV cannulae (14–16 gauge) and commence crystalloid fluid resuscitation.
Restrictive Red Blood Cell Transfusion Strategy: Landmark randomized trials (TRIGGER and RESTRICT) demonstrate that liberal transfusion strategies increase portal and splanchnic venous pressures, overcome physiological vasoconstriction, dislodge fragile platelet-fibrin clots, and significantly increase rebleeding rates and overall mortality .
Standard Threshold: Transfuse packed red blood cells only when haemoglobin falls below 70 g/L , targeting a post-transfusion haemoglobin of 70–80 g/L .
Cardiovascular Disease Threshold: In patients with active acute coronary syndromes, severe pre-existing ischaemic heart disease, or symptomatic cerebral vascular disease, a higher transfusion threshold of <80 g/L is applied, targeting a post-transfusion haemoglobin of 80–90 g/L .
Coagulopathy Management:
Platelet transfusion is indicated if active bleeding occurs with a platelet count <50 x 10^9/L.
Fresh frozen plasma (FFP) is administered if the prothrombin time ratio / INR >1.5 or fibrinogen <1.5 g/L (or cryoprecipitate if fibrinogen remains low despite FFP).
In patients taking warfarin with life-threatening bleeding, administer four-factor prothrombin complex concentrate (PCC) (25–50 units/kg) alongside intravenous vitamin K (5–10 mg) to achieve immediate, sustained reversal.
For direct oral anticoagulants (DOACs): administer idarucizumab for dabigatran reversal, or andexanet alfa (or high-dose 4-factor PCC if unavailable) for factor Xa inhibitors (apixaban, rivaroxaban).
- Risk Stratification: Pre-Endoscopy vs Post-Endoscopy
- The Glasgow-Blatchford Score (GBS)
The Glasgow-Blatchford Score is a validated, sensitive scoring tool calculated strictly prior to endoscopy at presentation. It determines the requirement for urgent clinical intervention (blood transfusion, endoscopic therapy, or surgical haemostasis) and identifies very low-risk patients who can be safely managed in the outpatient setting without admission.
- Admission Variable Parameter Value Score Points
- Blood Urea (mmol/L) >=6.5 to <8.0; >=8.0 to <10.0; >=10.0 to <25.0; >=25.0 2; 3; 4; 6
- Haemoglobin (g/L) for Men 120–129; 100–119; <100 1; 3; 6
- Haemoglobin (g/L) for Women 100–119; <100 1; 6
- Systolic Blood Pressure (mmHg) 100–109; 90–99; <90 1; 2; 3
- Pulse Rate >=100 bpm 1
- Presentation Features Syncope at presentation; Melaena at presentation 2; 1
- Comorbid Illness Underlying hepatic disease; Underlying cardiac failure 2; 2
Clinical Decision Rules:
GBS Score = 0: Extremely low risk (<0.5% mortality; essentially 0% need for intervention). Patients can be safely discharged directly from the emergency department for outpatient investigation .
GBS Score >=1: Inpatient admission and diagnostic gastroscopy indicated.
GBS Score >=6: Associated with high intervention rates (>50%) and high mortality, warranting urgent resuscitation and early endoscopy within 12–24 hours.
The Rockall Score
Unlike the GBS, the complete Rockall Score assesses post-procedure mortality and rebleeding risk by incorporating patient clinical variables (age, shock, comorbidity) with endoscopic findings (endoscopic diagnosis and stigmata of recent haemorrhage). A complete score <3 carries low risk of rebleeding and mortality (<5%), whereas a score >=8 confers an ominous mortality risk exceeding 40%.
- 2. Non-Variceal Upper GI Bleeding: Peptic Ulcers
- Endoscopic Timing & The Forrest Classification
Endoscopy should be performed within 24 hours of presentation in all admitted patients, and within 12 hours in haemodynamically unstable patients following initial resuscitation. The Forrest Classification grades the risk of rebleeding in peptic ulcer disease and dictates whether endoscopic therapy is mandatory:
Forrest Class Endoscopic Description Risk of Rebleeding Without Therapy Endoscopic Intervention Mandated?
- Forrest Ia Active arterial spurting haemorrhage ~90% Yes (Dual Therapy)
- Forrest Ib Active oozing haemorrhage ~10–30% Yes (Dual Therapy)
- Forrest IIa Non-bleeding visible vessel ~50% Yes (Dual Therapy)
- Forrest IIb Adherent clot on ulcer base ~25–30% Target irrigation; treat if underlying vessel
- Forrest IIc Flat pigmented haematin spot ~7–10% No
- Forrest III Clean ulcer base <3% No
- Endoscopic Haemostatic Modalities
High-Risk Lesions (Forrest Ia, Ib, IIa): Guidelines from NICE and ESGE strictly mandate endoscopic dual therapy . Dilute adrenaline injection (1:10,000, which provides local volume tamponade and transient alpha-1 vasoconstriction) must always be combined with a definitive secondary mechanical or thermal modality :
Mechanical: Through-the-scope haemostatic clips (TTS clips) or over-the-scope clips (OTSC), which achieve permanent mechanical vascular occlusion.
Thermal: Contact thermal coagulation (heater probe, bipolar electrocoagulation) or non-contact thermal therapy (argon plasma coagulation).
Critical Rule: Adrenaline monotherapy is strictly contraindicated and unacceptable because local vasoconstriction dissipates within 15–20 minutes, leading to unacceptably high rebleeding rates (>30%).
Pharmacological Therapy:
Post-Endoscopic IV PPI Infusion: For high-risk ulcers successfully treated endoscopically (Forrest Ia–IIa), administer high-dose intravenous PPI : an 80 mg intravenous bolus of omeprazole/pantoprazole, followed by a continuous infusion of 8 mg/hour for 72 hours (or 40 mg IV twice daily). Acid suppression maintaining intragastric pH >6.0 irreversibly inactivates pepsin and prevents pepsin-mediated fibrin clot lysis, preserving platelet aggregation.
Management of Rebleeding: Occurs in 10–15% of high-risk ulcers. First-line management is repeat urgent endoscopy. If endoscopic haemostasis fails a second time, immediately proceed to transcatheter arterial embolisation (TAE) via interventional radiology, or emergency surgical under-running of the bleeding vessel.
3. Variceal Upper GI Bleeding
Variceal haemorrhage arises from ruptured gastro-oesophageal varices secondary to clinically significant portal hypertension (hepatic venous pressure gradient [HVPG] >=12 mmHg, normal <=5 mmHg). It carries a formidable 6-week mortality of 15–20%.
Acute Emergency Management Bundle
Treatment must be initiated immediately upon clinical suspicion of variceal bleeding , before the patient is transferred to the endoscopy suite:
Pre-Endoscopic Vasoactive Therapy: Administer immediately:
Terlipressin: Synthetic vasopressin analogue (initial dose 2 mg IV bolus 4-hourly, reduced to 1 mg 4-hourly once haemostasis is secured, continued for up to 48–72 hours). Induces selective splanchnic vasoconstriction via V1 vascular receptors, reducing portal blood flow and lowering HVPG. Adverse effects: Peripheral ischaemia, hyponatraemia, and coronary vasoconstriction (use cautiously in ischaemic heart disease).
Octreotide / Somatostatin: Somatostatin analogue (50 mcg IV bolus followed by 50 mcg/hour continuous infusion). Alternative to terlipressin with fewer ischaemic side effects.
Prophylactic Broad-Spectrum Antibiotics: Administer intravenous Ceftriaxone 1 g once daily (or oral/IV ciprofloxacin) for 5–7 days. Up to 50% of cirrhotic patients with UGIB develop spontaneous bacterial peritonitis (SBP), pneumonia, or bacteremia; antibiotic prophylaxis dramatically reduces bacterial translocation, rebleeding rates, and overall in-hospital mortality.
Restrictive Transfusion: Target haemoglobin 70–80 g/L. Over-transfusion expands plasma volume, elevates portal venous pressure, and precipitates early catastrophic rebleeding.
Endoscopic Intervention (Within 12 Hours)
Oesophageal Varices: Endoscopic Variceal Band Ligation (EVBL) is the intervention of choice. Elastic bands are placed around variceal columns starting at the gastro-oesophageal junction and extending proximally. Endoscopic sclerotherapy is reserved only for when banding is technically impossible due to severe active haemorrhage obscuring the endoscopic field.
Gastric Varices: Fundal varices (Gastro-Oesophageal Varices type 2 [GOV2] or Isolated Gastric Varices type 1 [IGV1]) cannot be banded safely due to high rebleeding when bands slough off large vessels. Managed with endoscopic injection of N-butyl-2-cyanoacrylate (tissue adhesive / "superglue") mixed with Lipiodol, which polymerizes instantly upon contact with blood, obliterating the variceal lumen.
Salvage & Decompression Therapies
Balloon Tamponade (Sengstaken-Blakemore Tube): For massive, uncontrolled variceal bleeding refractory to medical and endoscopic therapy. The tube possesses a gastric balloon (inflated with 200–250 mL of air and retracted against the cardia) and an oesophageal balloon (inflated to 30–45 mmHg if bleeding persists). Serves purely as a temporary bridging measure (maximum duration 24 hours) to prevent fatal exsanguination while definitive therapy is arranged; prolonged inflation causes oesophageal ischaemic necrosis and perforation.
Transjugular Intrahepatic Portosystemic Shunt (TIPS): An artificial low-resistance tract created radiologically between the inflow portal vein and the outflow hepatic vein using an expanded polytetrafluoroethylene (ePTFE)-covered stent. Indications include:
Emergency Rescue TIPS: Failure of medical and endoscopic haemostasis.
Early / Pre-emptive TIPS (within 72 hours): In high-risk patients (Child-Pugh Class C, or Child-Pugh Class B with active bleeding at index endoscopy), early TIPS significantly reduces treatment failure and mortality.
Secondary Prophylaxis: Repeat EVBL every 2–4 weeks until complete variceal eradication, coupled with lifelong non-selective beta-blockers ( propranolol or carvedilol , which reduce cardiac output via beta-1 and provoke unopposed alpha-1 splanchnic vasoconstriction via beta-2 blockade).